AGIPNEWS8876

24/3/2011 13:10 GMT
ag-IP-news
AlphaRx Receives Notice of Allowance for US Patent

HONG KONG - AlphaRx Inc. announced in a press release that it has received a Notice of Allowance from the United States Patent and Trademark Office for its lead pain product candidate code named ARX8203, a potentially safer drug intended for pain treatment.

AlphaRx has developed three formulations using ARX8203, an injectable formulation for post-surgical pain, an oral capsule for chronic pain and an ophthalmic formulation for ocular inflammation.

AlphaRx has eight further US patent applications pending in different stages of examination and is confident that this is the first of many patents yet to receive allowance.

ARX8203 is a novel prodrug of a very potent FDA approved NSAID (non-steroidal, anti-inflammatory drug). ARX8203 has demonstrated excellent safety profile in G.I. toxicity studies compared with Diclofenac and Indomethacin, two very popular and currently marketed NSAIDs.

AlphaRx is a specialty pharmaceutical company utilizing proprietary drug delivery systems to develop novel formulations of drugs that are insoluble or poorly soluble in water or have yet to be administrable to the human body with an acceptable delivery method. The Company’s product candidates address various pharmaceutical markets, including pain and stroke.